DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01511393

Enrolling by invitation

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry

Lead sponsor

Novo Nordisk A/S

Assets

Dulaglutide / Exenatide / Liraglutide / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

6,750

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Annual incidence of MTC in the US to identify any possible increase related

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01511393
Org study IDNN2211-3965
Secondary IDU1111-1125-4362WHO

Timeline

Milestones

Study first posted2012-01-18estimated
Last update posted2023-06-13actual
Study start2012-01 (month precision)
Primary completion2039-12estimated (month precision)
Study completion2039-12estimated (month precision)

Assets

Investigational agents

DulaglutideExenatideLiraglutideSemaglutide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

People with medullary thyroid carcinoma invited by either written invitation from the participating cancer registry or the diagnosing physician to participate in the study.

Eligibility criteria

•A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
•At least 18 years or older.

There are no other inclusion or exclusion criteria.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Safety / tolerability / PK
2
Other clinical outcomes
1

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.

Time frame:Up to 15 years

event count, event

Secondary/protocol endpoint

Family history of cancer (including history of MEN2A or MEN 2B, history of FMTC, history of RET proto-oncogene mutations), Patient demographic characteristics, Patient prior history of thyroid diseases

Time frame:Up to 15 years

descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Lifestyle factors such as smoking and alcohol use

Time frame:Up to 15 years

descriptive

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Dose and Duration of use of all previous diabetes medication exposures (including long acting and short acting GLP-1 receptor agonists, DPP4 inhibitors, and insulin)

Time frame:Up to 15 years

descriptive

Secondary/protocol endpoint/low confidence

Dose and Duration of use of all previous weight management drugs (including long acting GLP-1 receptor agonists).

Time frame:Up to 15 years

descriptive

Secondary/protocol endpoint/low confidence

Environmental exposures (occupational history, radioiodine exposure, nuclear fallout)

Time frame:Up to 15 years

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.